Actinium Pharmaceuticals, a
New York based biopharmaceutical company specializing in the development of
cancer drugs, has important connections in both research and industry, and is
targeting a major market for which there is currently no approved drug.
In research, Actinium’s
patented technology was co-developed with Memorial Sloan Kettering Cancer
Center (MSKCC), one of the world’s most prestigious cancer centers. In
addition, Actinium’s largest shareholder, AHLB Holdings LLC, is wholly owned by
MSKCC. In industry, the company’s second largest shareholder is a subsidiary of
Merck & Co., one of the largest pharmaceutical companies in the world.
Actinium is focused on
treating cancer. Half of all men, and a third of all women, will develop at
least one form of cancer during their lifetime. The U.S. alone registers 1.5
million new cancer cases annually, with over 12 million worldwide, and this doesn’t
include non-melanoma skin cancers. Worldwide sales of biopharmaceutical
products for treating cancer are approximately $50 billion per year with U.S.
sales being approximately half of that.
Actinium is currently
developing blood cancer therapies, built on proprietary Alpha Particle
Immunotherapy (APIT) technology. The company’s primary drug candidate, Iomab-B,
is for the treatment of acute myeloid leukemia, and is already prepared to
enter a pivotal Phase III trial, which may lead to FDA approval. Iomab-B is
developed for patients age 55 or older who suffer from acute myeloid leukemia,
one of the deadliest of blood cancers for which there are no approved drugs.
Another drug, Actimab-A, also for acute myeloid leukemia, is on track to
produce Phase I/II interim data in 4Q 2014.
Actinium’s market potential
is further strengthened by the fact that its highly patented platform
technology could be used to target a wide variety of cancers. Preclinical and
clinical work has already focused on Non-Hodgkin Lymphoma (NHL), brain cancer,
bladder cancer, ovarian cancer, breast cancer, prostate cancer, and a number of
other cancer related indications. (Algeta, a company with similar technology,
was recently bought by Bayer for $2.4 billion.)
For additional information,
visit www.ActiniumPharmaceuticals.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
